Potential of glycyrrhizic and glycyrrhetinic acids against influenza type A and B viruses: A perspective to develop new anti-influenza compounds and drug delivery systems.
Langer D, Mlynarczyk DT, Dlugaszewska J, Tykarska E.
Eur J Med Chem. 2023 Jan 15;246:114934. doi: 10.1016/j.ejmech.2022.114934. Epub 2022 Nov 14.
PMID:36455358
An Intranasal Multivalent Epitope-Based Nanoparticle Vaccine Confers Broad Protection against Divergent Influenza Viruses.
Pan J, Wang Q, Qi M, Chen J, Wu X, Zhang X, Li W, Zhang XE, Cui Z.
Reduced Influenza B-Specific Postvaccination Antibody Cross-reactivity in the B/Victoria Lineage-Predominant 2019/20 Season.
Xie H, Xiang R, Wan HJ, Plant EP, Radvak P, Kosikova M, Li X, Zoueva O, Ye Z, Wan XF.
Clin Infect Dis. 2021 Jun 1;72(11):e776-e783. doi: 10.1093/cid/ciaa1481.
PMID:32990724
ANTIBODIES AGAINST INFLUENZA VIRUS TYPES A AND B IN CANADIAN SEALS.
Measures LN, Fouchier RAM.
J Wildl Dis. 2021 Oct 1;57(4):808-819. doi: 10.7589/JWD-D-20-00175.
PMID:34410421
When "B" becomes "A": the emerging threat of influenza B virus.
Sharma L, Rebaza A, Dela Cruz CS.
Eur Respir J. 2019 Aug 15;54(2):1901325. doi: 10.1183/13993003.01325-2019. Print 2019 Aug.
PMID:31416813
The Influenza B Virus Victoria and Yamagata Lineages Display Distinct Cell Tropism and Infection-Induced Host Gene Expression in Human Nasal Epithelial Cell Cultures.
Wilson JL, Akin E, Zhou R, Jedlicka A, Dziedzic A, Liu H, Fenstermacher KZJ, Rothman RE, Pekosz A.